ConductScience.org, home

Paper283266

Chemical carcinogenesis in nude mice: comparison between nude mice from homozygous matings and heterozygous matings and effect of age and carcinogen dose.

Stutman O. J Natl Cancer Inst, 1979. Cited by 95 papers, by iCite.

Cite this record

ConductScience Library. Chemical carcinogenesis in nude mice: comparison between nude mice from homozygous matings and heterozygous matings and effect of age and carcinogen dose. Papers, record 283266. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/283266

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Chemical carcinogenesis in nude mice: comparison between nude mice from homozygous matings and heterozygous matings and effect of age and carcinogen dose.
PubMed
Journal
J Natl Cancer Inst
PubMed
Year
1979
PubMed
Publication types
Comparative Study, Journal Article, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
95
iCite
Relative citation ratio, by iCite
1.75
iCite
Revised in PubMed
2021-12-03
PubMed

Authors1

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Stutman OO

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
MethylcholanthreneMajor topic
Mice, NudeMajor topic
Sarcoma, ExperimentalMajor topic
Age Factors
Animals
Dose-Response Relationship, Drug
Female
Heterozygote
Homozygote
Immunosuppression Therapy
Male
Mice
Mice, Inbred CBA
Pregnancy
Time Factors

Source PubMed

Download CSV of topics

Cited by37

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 95 citations.

PMIDTitleJournalYearIn PapersSource
4264998325 Years of Cancer Immunoediting: Dendritic Cells and Macrophages Filled the Missing Gap.Cancers (Basel)2026https://conductscience.org/library/papers/42649983PubMed
38042584Recent advances in immunopeptidomic-based tumor neoantigen discovery.Adv Immunol2023https://conductscience.org/library/papers/38042584PubMed
36672607Association between Immunosuppressive Therapy Utilized in the Treatment of Autoimmune Disease or Transplant and Cancer Progression.Biomedicines2022https://conductscience.org/library/papers/36672607PubMed
34697663Malignancy: An Adverse Effect of Immunosuppression.Handb Exp Pharmacol2022https://conductscience.org/library/papers/34697663PubMed
31921205The Intriguing History of Cancer Immunotherapy.Front Immunol2019https://conductscience.org/library/papers/31921205PubMed
31831634Impact of TCR Diversity on the Development of Transplanted or Chemically Induced Tumors.Cancer Immunol Res2020https://conductscience.org/library/papers/31831634PubMed
31557983Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward?Antibodies (Basel)2015https://conductscience.org/library/papers/31557983PubMed
31216652Multifaceted Role of the Placental Growth Factor (PlGF) in the Antitumor Immune Response and Cancer Progression.Int J Mol Sci2019https://conductscience.org/library/papers/31216652PubMed
29900059The possibility of cancer immune editing in gliomas. A critical review.Oncoimmunology2018https://conductscience.org/library/papers/29900059PubMed
29311379A Believer's Overview of Cancer Immunosurveillance and Immunotherapy.J Immunol2018https://conductscience.org/library/papers/29311379PubMed
28609371Orthotopic Patient-Derived Pancreatic Cancer Xenografts Engraft Into the Pancreatic Parenchyma, Metastasize, and Induce Muscle Wasting to Recapitulate the Human Disease.Pancreas2017https://conductscience.org/library/papers/28609371PubMed
28534024Cancer Immunoprevention and Public Health.Front Public Health2017https://conductscience.org/library/papers/28534024PubMed
26922999The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer.Adv Immunol2016https://conductscience.org/library/papers/26922999PubMed
26464579Curcumin and tumor immune-editing: resurrecting the immune system.Cell Div2015https://conductscience.org/library/papers/26464579PubMed
26435343Tolerance and immune suppression in the tumor microenvironment.Cell Immunol2016https://conductscience.org/library/papers/26435343PubMed
24860566Induced pluripotent stem cells: challenges and opportunities for cancer immunotherapy.Front Immunol2014https://conductscience.org/library/papers/24860566PubMed
24657536The importance of animal models in tumor immunity and immunotherapy.Curr Opin Genet Dev2014https://conductscience.org/library/papers/24657536PubMed
24324471Tumor-primed NK cells: waiting for the green light.Front Immunol2013https://conductscience.org/library/papers/24324471PubMed
24133490How numbers, nature, and immune status of foxp3(+) regulatory T-cells shape the early immunological events in tumor development.Front Immunol2013https://conductscience.org/library/papers/24133490PubMed
22936035Improving T cell responses to modified peptides in tumor vaccines.Immunol Res2013https://conductscience.org/library/papers/22936035PubMed

See all 37 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/283266

GET https://conductscience.org/api/papers/v1/283266/cited_by?page=2